Psychopharmacology Bulletin
The Revised Dopamine Hypothesis of Schizophrenia: Evidence From Pharmacological MRI Studies With Atypical Antipsychotic Medication CME

Disclosures

Release Date: March 25, 2008; Valid for credit through March 25, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

  1. The Revised Dopamine Hypothesis of Schizophrenia: Evidence From Pharmacological MRI Studies With Atypical Antipsychotic Medication
    Fabiana da Silva Alves, MS
    Martijn Figee, MD
    Therese van Amelsvoort, MD, PhD
    Dick Veltman, MD, PhD
    Lieuwe de Haan, MD, PhD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the dopamine hypothesis of schizophrenia
  2. Identify the most commonly used radiologic methods for the in vivo study of schizophrenia
  3. List the negative symptoms of schizophrenia
  4. Identify the part of the brain most likely to be involved in the action of atypical antipsychotic agents
  5. Describe the dopamine activity pattern according to the revised dopamine hypothesis of schizophrenia
Authors and Disclosures

Fabiana da Silva Alves, MS
Disclosure: Fabiana da Silva Alves, MS, has no financial relationships to disclose


Martijn Figee, MD
Disclosure: Martijn Figee, MD, has no financial relationships to disclose.


Therese van Amelsvoort, MD, PhD
Disclosure: Therese van Amelsvoort, MD, PhD, has no financial relationships to disclose.


Dick Veltman, MD, PhD
Disclosure: Dick Veltman, MD, PhD, has no financial relationships to disclose.


Lieuwe de Haan, MD, PhD
Disclosure: Lieuwe de Haan, MD, PhD, has no financial relationships to disclose.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.